This study aimed to confirm the role of the TP53 mutation in advanced NSCLC patients treated with third‐generation EGFR‐TKIs as first‐line treatment or after the failure of a previous EGFR‐TKIs treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.